目的 探讨复方鱼腥草糖浆联合罗红霉素治疗急性咽炎的安全性与有效性。方法 选取河南省中医院于2016年3月-2017年3月收治的急性咽炎患儿125例，随机分对照组（62例）和治疗组（63例）。对照组患者口服罗红霉素胶囊，体质量12~23 kg剂量为50 mg/次，体质量24~40 kg剂量为100 mg/次，2次/d；治疗组患者在对照组基础上口服复方鱼腥草糖浆，1支/次，2次/d。两组患者均连续治疗7 d。观察两组患者临床疗效，同时比较治疗前后两组患者临床体征缓解时间、炎症指标水平和不良反应情况。结果 治疗后，对照组和治疗组临床有效率分别为82.26%和95.24%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者咽喉肿痛消失时间、淋巴消肿时间和分泌物减少时间均显著短与对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者白细胞计数、C反应蛋白和肿瘤坏死因子-α（TNF-α）水平均较治疗前显著降低（P<0.05），且治疗组这些炎症指标患者比对照组降低更明显（P<0.05）。治疗期间，治疗组患者药物不良反应发生率为3.17%，显著低于对照组患者的14.52%，两组比较差异具有统计学意义（P<0.05）。结论 复方鱼腥草糖浆联合罗红霉素治疗急性咽炎疗效显著、安全性高，具有一定的临床推广应用价值。

Objective To investigate the safety and efficacy of Compound Yuxingcao Syrup combined with roxithromycin in treatment of children with acute pharyngitis. Methods Patients (125 cases) with acute pharyngitis in Henan Province Hospital of TCM from March 2016 to March 2017 were randomly divided into control (62 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Roxithromycin Capsules, 50 mg/time for 12-23 kg children, 100 mg/time for 24-40 kg children, twice daily. Patients in the treatment group were po administered with Compound Yuxingcao Syrup on the basis of the control group, 1 branch/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the remission time of clinical signs, the inflammation indexes levels and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.26% and 95.24%, respectively, and there were differences between two groups (P < 0.05). After treatment, the disappearance time of swelling and pain in throat, the time of lymphedema detumescence and secretion reduction in the treatment group after treatment was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the white blood cell count, CRP, and TNF-α levels in two groups were significantly decreased (P < 0.05), and these inflammation indexes in the treatment group after treatment were significantly lower than those in the control group (P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 3.17%, which was significantly lower than 14.52% in the control group, with significant difference between two groups (P < 0.05). Conclusion Compound Yuxingcao Syrup combined with roxithromycin in treatment of children with acute pharyngitis has significant efficacy and safety, which has a certain clinical application value.